On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with uncomplicated urinary tract infections (uUTIs). The FDA has granted Priority Review for this application and assigned a Prescription Drug User Fee Act (PDUFA) action date of March 26, 2025. Also Read: GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement. Over half of all women are affected by uUTIs in their lifetime, with approximately 30% suffering from recurrent disease. New treatments are needed as the num…
